James Boiani, Senior Counsel in the Health Care and Life Sciences practice, in Washington, DC, was quoted in an article titled "Strategic Perspectives: Drug and Device Developments: 2014 Q2 Update."
Following is an excerpt:
This June, the FDA issued three draft guidance documents on the advertising and promotion of drugs and devices. In an interview with Wolters Kluwer, James A. Boiani, a Senior Counsel in the Health Care and Life Sciences Practice of Epstein Becker Green's Washington, D.C. office, stated that response to these three draft guidance documents by industry "has been mixed, but the fact that the FDA is re-starting the dialogue regarding its restrictions on free speech by releasing these drafts is a promising sign." Boiani recommends that stakeholders "get very engaged and address [to FDA] the value of disseminating truthful and non-misleading information that can help patients and physicians make better decisions."